Search
7MW3711
go.drugbank.com/drugs/DB19298InvestigationalDeveloped by Mabwell, 7MW3711 is an antibody-drug conjugate targeting B7-H3.[L50918,L50923]
Girentuximab
go.drugbank.com/drugs/DB05304InvestigationalGirentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC).
IR208
go.drugbank.com/drugs/DB05106InvestigationalIR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation. … It contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial.
Pimicotinib
go.drugbank.com/drugs/DB18972InvestigationalIt was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]
Synonyms: 1-Pyrrolidinecarboxamide, 3,3-dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-, 3,3-Dimethyl-N-[6-methyl-5-[[2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-oxo-1-pyrrolidinecarboxamideBouteloua gracilis pollen
go.drugbank.com/drugs/DB10715ApprovedBouteloua gracilis pollen is the pollen of the Bouteloua gracilis plant. Bouteloua gracilis pollen is mainly used in allergenic testing.
Categories: Non-Standardized Pollen Allergenic ExtractPhalaris minor pollen
go.drugbank.com/drugs/DB10963ApprovedPhalaris minor pollen is the pollen of the Phalaris minor plant. Phalaris minor pollen is mainly used in allergenic testing.
Categories: Non-Standardized Pollen Allergenic ExtractManitimus
go.drugbank.com/drugs/DB06481InvestigationalFK778, a novel compound with multiple mechanisms of action, is efficacious, well tolerated and safe in kidney transplant patients, potentially offering a breakthrough in immunosuppressive therapy.
Synonyms: (2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide, (2Z)-2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHLY)PHENYL)-2-HEPTEN-6-YNAMIDEHuman ciliary neurotrophic factor, recombinant (E. coli)
go.drugbank.com/drugs/DB17959ExperimentalThe trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia